Removal of Fish Bones Embedded in the Hypopharynx Using a Novel Snare Device.

J Emerg MedAug 20, 2026 (epub)
Case ReportOtolaryngology (ENT)Emergency Medicine

Aaron E Robinson, Brian E Driver, Matthew E Prekker et al.

✦ AI-curated · Sources linked

Case in brief

Three adult patients presented to the emergency department with fish bones embedded in the pharyngeal mucosa. Conventional removal techniques by emergency physicians and otolaryngologists were unsuccessful, necessitating operating room intervention. However, a novel snare device, constructed from readily available ED supplies, successfully removed the fish bones in all cases, eliminating the need for surgical consultation.

Diagnostic / clinical pearl

Emergency clinicians should consider using improvised snare devices for the removal of foreign bodies from the hypopharynx when conventional methods fail.

Source

PubMed · PMID 42759271

Published in J Emerg Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.